| 来源类型 | Working Paper |
| 规范类型 | 报告 |
| DOI | 10.3386/w14009 |
| 来源ID | Working Paper 14009 |
| Pharmaceutical innovation and the longevity of Australians: a first look | |
| Frank R. Lichtenberg; Gautier Duflos | |
| 发表日期 | 2008-05-15 |
| 出版年 | 2008 |
| 语种 | 英语 |
| 摘要 | We examine the impact of pharmaceutical innovation on the longevity of Australians during the period 1995-2003. Due to the government's Pharmaceutical Benefits Scheme, Australia has much better data on drug utilization than most other countries. We find that mean age at death increased more for diseases with larger increases in mean drug vintage. The estimates indicate that increasing the mean vintage of drugs by 5 years would increase mean age at death by almost 11 months. The estimates also indicate that using newer drugs reduced the number of years of potential life lost before the ages of 65 and 70 (but not before age 75). During the period 1995-2003, mean age at death increased by about 2.0 years, from 74.4 to 76.4. The estimates imply that, in the absence of any increase in drug vintage, mean age at death would have increased by only 0.7 years. The increase in drug vintage accounts for about 65% of the total increase in mean age at death. We obtain a rough estimate of the cost per life-year gained from using newer drugs. Under our assumptions, using newer drugs (increasing drug vintage) increased life expectancy by 1.23 years and increased lifetime drug expenditure by $12,976; the cost per life-year gained from using newer drugs is $10,585. An estimate made by other investigators of the value of a statistical Australian life-year ($70,618) is 6.7 times as large as our estimate of the cost per life-year gained from using newer drugs. We discuss several reasons why our estimate of the cost per life-year gained from using newer drugs could be too high or too low. |
| 主题 | Public Economics ; National Fiscal Issues ; Health, Education, and Welfare ; Health ; Labor Economics ; Demography and Aging ; Development and Growth ; Innovation and R& ; D ; Country Studies |
| URL | https://www.nber.org/papers/w14009 |
| 来源智库 | National Bureau of Economic Research (United States) |
| 引用统计 | |
| 资源类型 | 智库出版物 |
| 条目标识符 | http://119.78.100.153/handle/2XGU8XDN/571683 |
| 推荐引用方式 GB/T 7714 | Frank R. Lichtenberg,Gautier Duflos. Pharmaceutical innovation and the longevity of Australians: a first look. 2008. |
| 条目包含的文件 | ||||||
| 文件名称/大小 | 资源类型 | 版本类型 | 开放类型 | 使用许可 | ||
| w14009.pdf（140KB） | 智库出版物 | 限制开放 | CC BY-NC-SA | 浏览 | ||
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
